8-K: iRadimed Reports Record Preliminary Unaudited Fourth Quarter and Full-Year 2024 Revenues

iRadimed announced record preliminary unaudited revenues for the fourth quarter and full-year 2024, with strong year-over-year and sequential growth.

Summary

• iRadimed has released preliminary unaudited revenue figures for the fourth quarter and full year of 2024.
• The company expects fourth-quarter revenue to be between $19.2 million and $19.4 million.
• This represents a year-over-year growth of 10% to 11% and a sequential quarter-over-quarter growth of 5% to 6%.
• Full-year 2024 revenue is anticipated to be between $73.1 million and $73.3 million.
• This is an increase of 11% to 12% compared to the $65.6 million reported in the previous year.
• The company has achieved its highest quarterly revenue to date and has now recorded fourteen consecutive quarters of record-breaking revenues.
• Orders booked in the fourth quarter exceeded shipments, resulting in a strong backlog.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to record revenues, strong growth, and a robust backlog. The company's outlook for continued demand is also encouraging.

Positives

• The company experienced strong year-over-year and sequential revenue growth in the fourth quarter of 2024.
• iRadimed has achieved a record high quarterly revenue.
• The company has a strong backlog due to orders exceeding shipments.
• There is increasing demand for the company's products.
• The company expects the increasing demand trend to continue throughout 2025.

Risks

• The reported figures are preliminary and unaudited, and actual revenues may differ.
• The company's future performance is subject to various risks and uncertainties, as detailed in their SEC filings.

Future Outlook

iRadimed expects the increasing demand for its products to continue throughout 2025.

Management Comments

• Roger Susi, President and CEO, stated that the fourth quarter of 2024 marked the company's highest quarterly revenue to date.
• Roger Susi also noted that the company has achieved fourteen consecutive quarters of record-breaking revenues.
• Management highlighted that orders booked in the fourth quarter exceeded shipments, providing a robust backlog.

Industry Context

This announcement highlights iRadimed's continued growth in the MRI-compatible medical device market, where their specialized products address a critical need for safe and reliable equipment during MRI procedures.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, iRadimed's consistent revenue growth and record-breaking quarters suggest a strong position in the niche market of MRI-compatible medical devices.
• Companies like Medtronic and Philips also operate in the broader medical device space, but iRadimed's focus on MRI compatibility gives them a unique advantage.
• The company's growth rate of 10-12% year-over-year is a positive indicator compared to the broader medical device industry growth rates.

Stakeholder Impact

• Shareholders are likely to react positively to the record revenue and growth.
• Employees may be motivated by the company's success and positive outlook.
• Customers benefit from the company's innovative and reliable MRI-compatible medical devices.
• Suppliers may see increased demand for their products due to iRadimed's growth.

Next Steps

• iRadimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
• The company will continue to monitor demand and expects it to increase throughout 2025.

Key Dates

Keywords

iRadimed, MRI compatible devices, medical devices, revenue, financial results, infusion pump, patient monitoring, healthcare, medical technology